Seeking Alpha

Roche Holding Ltd ADR (RHHBY)

  • Mon, Jun. 1, 8:56 AM
    • Micro cap Vascular Biogenics (NASDAQ:VBLT) is up 11% premarket on robust volume in response to its announcement of positive interim results from a Phase 2 study assessing its lead product candidate, VB-111, in patients with recurrent glioblastoma (rGBM), one of the most aggressive primary brain tumors. The data showed a statistically significant benefit in overall survival (OS) in patients treated with VB-111 followed by VB-111 in combination with Roche's (OTCQX:RHHBY) Avastin (bevacizumab) upon disease progression compared to patients treated with VB-111 followed by bevacizumab alone (p=0.05). The full results were presented earlier this morning at a meeting for investors in conjunction with ASCO.
    • 46 patients with rGBM were treated with VB-111. Upon disease progression, 23 were treated with VB-111 + bevacizumab and 22 received bevacizumab alone (one patient was stable on VB-111 alone after 18 months). Median OS in the combination arm was 16 months compared to eight months in the bevacizumab alone arm (p=0.05).
    • VB-111 is an anti-angiogenic agent which is designed to restrict tumor growth by inhibiting the proliferation of new blood vessels that form to support rapidly growing cells.
    • The company intends to initiate a Phase 3 trial later this year.
    | Mon, Jun. 1, 8:56 AM | 1 Comment
  • Mon, Jun. 1, 8:09 AM
    • TheStreet's Adam Feuerstein reports from ASCO in Chicago. On the plus side, he says Oncothyreon (NASDAQ:ONTY), Roche (OTCQX:RHHBY), Merck (NYSE:MRK), ImmonoGen (NASDAQ:IMGN), Celldex Therapeutics (NASDAQ:CLDX) and CTIBiopharma (NASDAQ:CTIC) all presented impressive data.
    • On the negative side, Clovis Oncology (NASDAQ:CLVS) and Puma Biotech (NYSE:PBYI) fell short of wowing the crowd while Bristol-Myers Squibb (NYSE:BMY) was a bit of a mixed bag.
    | Mon, Jun. 1, 8:09 AM | 5 Comments
  • Fri, May 29, 5:24 PM
    • Bristol-Myers Squibb (NYSE:BMY) stumbled 7% today on a 4.5x surge in volume in response to the presentation of an abstract (#109) at ASCO that underwhelmed many investors. The data were from Phase 3 study, called CheckMate-057, assessing the company's PD-1 inhibitor, Opdivo (nivolumab) compared to the standard-of-care chemotherapy agent docetaxel in treatment-experienced patients with advanced, non-squamous non-small cell lung cancer, the most common form of lung cancer. A drug used after another (treatment experienced) is called a second line setting.
    • The study met its primary endpoint of a statistically significant 27% reduction in the risk of cancer progression or death compared to docetaxel (p=0.0015). The trial also evaluated the efficacy of Opdivo compared to docetaxel by the level of PD-L1 expression, 1%, 5% and 10%. As expected, the median overall survival (OS) in the Opdivo group was significantly longer than the chemo cohort for all three levels where PD-L1 was highly expressed (greater than or equal to 1, 5, 10%).
    • What raised eyebrows was the absence of a treatment benefit compared to docetaxel in the three groups with low PD-L1 expression (<1%, <5%, <10%). Median OS was barely higher in the Opdivo group with <1% expression and lower than docetaxel in the other two. This potentially opens the door for eventual competitors such as Roche (OTCQX:RHHBY) and Merck (NYSE:MRK) whose offerings show strong efficacy in tumors that highly express PD-L1. Had Opdivo shown a significant OS advantage in low PD-L1 expression tumors, its dominance in the second line setting would have been virtually assured.
    • CheckMate-057 was stopped early based on the successful achievement of its primary endpoint, per the recommendation of the independent Data Monitoring Committee.
    • Previously: Phase 3 study stopped early after Bristol-Myers' Opdivo hits efficacy endpoint (April 17)
    | Fri, May 29, 5:24 PM | 11 Comments
  • Thu, May 28, 7:19 AM
    • Roche (OTCQX:RHHBY) enters into an exclusive license agreement with Bern, Switzerland-based Galenica for the commercialization of Mircera (methoxy polyethylene glycol-epoetin beta) in the U.S. and Puerto Rico.  Mircera is a long-acting erythropoietin stimulating agent indicated for the treatment of anemia associated with chronic kidney disease in adult patients.
    • Under the terms of the agreement, Roche will receive upfront and milestone payments, supply reimbursements and tiered royalties. Specific financial terms are not disclosed.
    • Galenica has entered into a supply agreement with Fresenius Medical Care of North America under which Galenica will supply Mircera to its dialysis facilities.
    • The FDA approved Mircera in November 2007 but the launch was delayed due to patent infringement issues with Amgen.
    | Thu, May 28, 7:19 AM | Comment!
  • Tue, May 26, 1:14 PM
    • Quintiles Transnational Holdings (Q +0.2%) upgraded to Buy from Neutral by SunTrust Robinson Humphrey.
    • ReWalk Robotics (RWLK +1.6%) upgraded to Buy from Hold by Canaccord Genuity.
    • Ilumina (ILMN) upgraded to Overweight from Equal-Weight by Morgan Stanley but price target lowered to $162 (21% downside risk) from $190. Current price: ~$205.
    • Sarepta Therapeutics (SRPT +1.6%) upgraded to Buy from Hold with a $30 (12% upside) price target by Canaccord Genuity.
    • Roche (OTCQX:RHHBY -1.4%) upgraded to Buy from Neutral with a CHF325 (18% upside) price target by UBS.
    • Sarepta Therapeutics downgraded to Neutral from Buy by Bank of America; price target raised to $28 (5% upside) from $20.
    • Bruker (BRKR -0.9%) downgraded to Neutral from Buy with a $22 (13% upside) price target by Mizuho Securities.
    • Achillion Pharmaceuticals (ACHN -0.3%) downgraded to Market Perform from Outperform by JMP Securities; $24 price target removed.
    • Intercept Pharmaceuticals (ICPT) downgraded to Neutral from Buy with a $315 (21% upside) price target by Bank of America.
    • Healthways (HWAY -1%) downgraded to Hold from Buy by Stifel Nicolaus; $25 price target removed.
    • AmerisourceBergen (ABC -0.4%) downgraded to Market Perform from Outperform with a $121 (7% upside) price target by Cowen & Co.
    | Tue, May 26, 1:14 PM | 2 Comments
  • Tue, May 26, 9:21 AM
    • The FDA approves privately-held Boehringer Ingelheim's once-daily Stiolto Respimat (tiotropium bromide and olodaterol) Inhalation Spray for the maintenance treatment of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. It is not cleared for the treatment of asthma or acute deterioration of COPD.
    • Tiotropium, a long-acting anticholinergic, is the active ingredient in Spiriva, the most prescribed COPD maintenance treatment worldwide. Olodaterol, a long-acting beta2-agonist that complements the efficacy of Spiriva, has a fast onset of action that improves airflow in five minutes after dosing.
    | Tue, May 26, 9:21 AM | 2 Comments
  • Wed, May 20, 1:14 PM
    • Thinly traded nano cap Lpath (LPTN -79.5%) craters on a massive 78x surge in volume in response to its announcement that its lead product candidate, iSONEP, failed to achieve its primary and key secondary efficacy endpoints in a Phase 2 trial in patients with wet age-related macular degeneration (wet AMD) who had not responded adequately to anti-vascular endothelial growth factor (VEGF) therapies such as Roche's (OTCQX:RHHBY -0.4%) Lucentis (ranibuzumab) or Avastin (bevacizumab) or Regeneron's (REGN +1.4%) Eylea (aflibercept).
    • Patients treated with iSONEP, either alone or as an adjunct, did not show any statistically significant improvement in visual acuity.
    • SVP and Chief Development Officer Dario Paggiarino, M.D., says, "This trial was designed to evaluate the activity of iSONEP in wet AMD patients that had previously received at least three prior injections of an anti-VEGF agent and had not responded well. While the primary endpoint of the trial was not met, we will be conducting a complete analysis of the data, including additional anatomical endpoints, to better understand the results from each arm of the trial."
    • iSONEP is a monoclonal antibody that binds to a bioactive lipid called sphingosine-1-phosphate, a major regulator of vascular systems.
    • Final results will be presented in November at the American Academy of Ophthalmology meeting in Las Vegas, NV.
    • Related ticker: (PFE +0.4%)
    | Wed, May 20, 1:14 PM | 5 Comments
  • Mon, May 18, 4:23 PM
    • Ilumina (NASDAQ:ILMN) files a lawsuit in the U.S. District Court for the Northern District of California against Roche (OTCQX:RHHBY) subsidiary Ariosa Diagnostics accusing it of infringing on U.S. Patent No. 7,955,794 entitled "Multiplex Nucleic Acid Reactions." The action is focused on Ariosa's Microarray-based version of its Harmony Prenatal Test.
    • Previously, Ilumina and its subsidiary Verinata Health filed suits in the same court accusing Ariosa of infringing the '794 patent as well as Patent Nos. 8,296,076 and 8,318,430 with the sequencing-based version of its Harmony Prenatal Test.
    | Mon, May 18, 4:23 PM | 3 Comments
  • Thu, May 14, 10:17 AM
    • Interim data from a Phase 2 trial, called POPLAR, evaluating Roche's (OTCQX:RHHBY +2.6%) investigational cancer immunotherapy, MPDL3280A, in treatment-experienced non-small cell lung cancer (NSCLC) patients showed a doubling of overall survival (OS) in those whose cancer expressed the highest levels of PD-L1 (programmed death ligand-1) compared to docetaxel chemotherapy. A less-profound improvement was observed in patients with medium/high PD-L1 expression.
    • MPDL3280A is a monoclonal antibody that inhibits PD-L1, a protein on the surface of cancer cells that plays a key role in suppressing the immune system by hindering the proliferation of CD8+T cells, the body's front-line attackers of foreign antigens.
    • Complete interim results from POPLAR (Abstract #8010) will be presented on the afternoon of May 31 at the American Society of Clinical Oncology meeting in Chicago, May 29 - June 2.
    • Previously: Roche's MPDL3280A a Breakthrough Therapy for NSCLC (Feb. 2)
    | Thu, May 14, 10:17 AM | 3 Comments
  • Thu, May 14, 10:00 AM
    • In separate Phase 1/2 studies, patients treated with Roche's (OTCQX:RHHBY +2.1%) alectinib demonstrated response rates as high as 68.8%. Patients with ALK-positive non-small cell lung cancer whose disease had progressed following treatment with crizotinib (Pfizer's Xalkori) showed an overall response rate (ORR) of  50% in Study NP28673 and 47.8% in Study NP28761. In patients whose cancer has spread to the central nervous system, the ORRs were 57.1% and 68.8%, respectively.
    • Alectinib is an anaplastic lymphoma kinase (ALK) inhibitor created at Chugai Kamakura Research Labs.
    • Complete results will be presented at the American Society of Clinical Oncology meeting in Chicago, May 29 - June 2. Study NP28673 (Abstact #8008) will be presented on the morning of May 31 and Study NP28761 (Abstract #8019) will be presented on the morning of June 1.
    | Thu, May 14, 10:00 AM | Comment!
  • Mon, May 11, 5:22 PM
    • Ophthotech (NASDAQ:OPHT) completes enrollment in its first Phase 3 trial assessing Fovista (anti-PDGF BB pegylated aptamer) in combination with Roche's (OTCQX:RHHBY) Lucentis (ranibizumab) compared to Lucentis alone as monotherapy in patients with wet age-related macular degeneration (wet-AMD).
    • Patient enrollment in a second Phase 3 study assessing Fovista + Lucentis compared to Lucentis alone should be completed by the end of Q3. Data readout from the first two studies should happen in 2016.
    • A third Phase 3 study evaluating Fovista in combination with Regeneron's (NASDAQ:REGN) Eylea (aflibercept) or Roche's Avastin (bevacizumab) compared to Eylea or Avastin alone should reach its enrollment target in the same time frame as the other two studies, although the expected time from today is unclear.
    • Total enrollment in the three trials will be ~1,866 across 225 sites worldwide.
    • The company's objective with Fovista is to be agnostic relative to the choice of anti-VEGF agent co-administered with it.
    | Mon, May 11, 5:22 PM | 5 Comments
  • Mon, May 11, 8:07 AM
    • The FDA approves Roche's (OTCQX:RHHBY) real-time PCR test for the KRAS genetic mutation in tumor samples from patients with metastatic colorectal cancer (mCRC). The test, which detects mutations in codons 12 and 13 of the KRAS gene, is performed on the company's cobas 4800 analyzer.
    • The new assay expand's the system's companion diagnostic menu to three: BRAF (melanoma), EGFR (lung cancer) and KRAS (mCRC).
    | Mon, May 11, 8:07 AM | Comment!
  • Fri, May 8, 9:23 AM
    • Nano cap Ohr Pharmaceuticals (NASDAQ:OHRP) presented results from the clinical trial that failed to show its eye drops for wet-AMD (wet form of age-related macular degeneration) were better than placebo at the Association for Research in Vision and Ophthalmology conference in Denver, CO. The company originally announced the data from the Phase 2 study, called IMPACT, in March. Shares plunged almost 70% on the news.
    • Data presented at the meeting in the modified intent-to-treat (mITT) population with classic containing lesions showed that patients treated with the combination of OHR-102 (0.2% squalamine lactate ophthalmic solution) and Roche's (OTCQX:RHHBY) Lucentis (ranibizumab injection) (n=37) had mean gains in visual acuity at Month 9 of +11 letters compared to +5 letters in the Lucentis + placebo cohort (n=28). 44% of patients receiving the combination therapy achieved an e3 line vision gain at Month 9 compared to 29% in the Lucentis + placebo group.
    • In the overall mITT population, patients with either classic containing or occult only lesions, the OHR-102 combination arm showed a less distinct benefit (+7.8 letters) compared to Lucentis + placebo (+5.3 letters).
    • The company appears undeterred by the failure of IMPACT. It plans to proceed to Phase 3 development in H2 targeting, no doubt, wet-AMD patients with classic containing lesions (classic choroidal neovascularization).
    • Previously: Ohr Pharma Phase 2 study of wet-AMD drug fails to hit primary endpoint; shares plummet 55% premarket (March 27)
    | Fri, May 8, 9:23 AM | 2 Comments
  • Thu, May 7, 11:13 AM
    • Spurred by the progress of a bill moving through Congress that will speed new drugs to market for conditions lacking cures, called The 21st Century Cures Act, the FDA has scheduled a public meeting this summer to address concerns by the drugs industry that regulatory restrictions on what they can say about the off-label use of their products violates their First Amendment right to free speech. Language in the bill is ratcheting up the pressure on the agency to relax its guidelines.
    • Drug makers were emboldened on its prospects of changing the rules after an appeals court overturned the conviction of a pharmaceutical sales representative in 2012 who was convicted of promoting off-label uses of the narcolepsy drug Xyrem. The court ruling was based on First Amendment protection for truthful and non-misleading off-label speech.
    • The American Medical Association supports the need for physicians to have access to accurate and unbiased information about off-label uses of drugs since it already accounts for as much as 20% of prescribing, with higher levels in oncology and pediatric rare diseases.
    • Giving drug firms more leeway in this arena has its detractors, however. Rita Redberg, M.D., Professor of Medicine at the UC-San Francisco says, "At my own medical center we have banned pharmaceutical reps from coming because we don't think they are a good source of information. You don't ask the barber if you need a haircut."
    • Pharma companies have a dubious history of breaking the rules governing off-label promotion. Over the past 10 years, 17 firms have paid more than $16B in settlements related to inappropriate off-label selling.
    • Further complicating matters is the fact that up to 75% of published pre-clinical trial results cannot be reproduced in later studies.
    • Related tickers: (MRK +0.4%)(LLY -0.1%)(PFE +0.3%)(BMY +0.7%)(GSK -4.1%)(OTCQX:RHHBY -1.1%)(SNY -0.6%)(OTCPK:BAYRY -0.5%)(NVS +0.1%)(AZN -0.3%)(JNJ +0.2%)(ABT -0.1%)(ABBV +0.1%)
    | Thu, May 7, 11:13 AM | 6 Comments
  • Thu, May 7, 7:23 AM
    • The FDA designates venetoclax (RG7601, GDC-0199/ABT-199) a Breakthrough Therapy for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia (CLL) who have genetic mutation known as a 17p deletion. Patients in this classification generally have poor prognoses.
    • Venetoclax selectively binds to and inhibits Bcl-2 proteins which play a key role in apoptosis (cell death). Bcl-2s are highly expressed in blood cancers. The drug candidate is being jointly developed by Roche (OTCQX:RHHBY) and AbbVie (NYSE:ABBV).
    • Breakthrough Therapy status allows for more intensive guidance from the FDA on the most efficient development path, the involvement of more senior agency personnel and a rolling review of the New Drug Application (NDA).
    | Thu, May 7, 7:23 AM | Comment!
  • Tue, May 5, 5:05 PM
    • Pacific Biosciences (NASDAQ:PACB) achieves a second development milestone under its 2013 collaboration agreement with Roche (OTCQX:RHHBY), triggering a $10M payment. Pac Bio has now earned $20M of the $40M potential milestones specified in the contract.
    • The agreement covers clinical diagnostic products, including sequencing systems and consumables based on Pac Bio's Single Molecule Real-Time (SMRT) technology. Under the terms of the agreement, Roche has the exclusive right to commercialize the products for clinical use, subject to certain terms and conditions.
    | Tue, May 5, 5:05 PM | Comment!
Visit Seeking Alpha's
RHHBY vs. ETF Alternatives
Company Description
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and... More
Sector: Healthcare
Country: Switzerland